Compare Abbott Laboratories (ABT) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Marvell Technology Inc — how do they compare? Abbott Laboratories trades at $95.6 (market cap $166.94B), while Marvell Technology Inc trades at $231.92 (market cap $202.28B). The key difference: Marvell Technology Inc is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | MRVL | |
|---|---|---|
Market Cap | $166.94B | $202.28B |
Sector | Health | Technology |
52-Week High | $136.62 | $316.43 |
52-Week Low | $82.57 | $62.31 |
Enterprise Value | $193.69B | $203.71B |
Dividend Yield | 2.63% | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Marvell Technology (MRVL) trades at $230.7, down 5.95% amid a sector-wide chip stock selloff. The stock shows strong earnings beats in recent quarters but faces high valuation multiples with a P/E of 85.7 and P/S of 25.0. Technical indicators are neutral, with support near $234 and resistance at $257. Revenue growth is projected to surge to $8.7B in 2026, with net income turning positive to $2.5B, signaling a potential fundamental turnaround.
Outlook: MRVL's AI infrastructure growth and analyst consensus target of $262.6 offer upside, but high valuations and margin pressures pose risks. Investor sentiment is mixed due to semiconductor volatility, though institutional backing remains strong with 82% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
